PLAINSBORO, N.J. — Novo Nordisk on Thursday announced the launch of Levemir FlexTouch (insulin detemir [rDNA origin] injection), a prefilled insulin delivery mechanism providing a new way for diabetics to administer their insulin.
The device is the first and only prefilled insulin delivery system without a push-button extension, which helps to eliminate delivery challenges for the patient, according to the company.
"The features of FlexTouch were designed to help patients administer their insulin," said Michael Shannon, M.D., chair of endocrinology and diabetes clinical advancement at Providence Health and Services. “The reduced reach and low injection force button are both advancements in improving the insulin delivery experience.”
FlexTouch was approved by the Food and Drug Administration in November 2013. The device also launched in other countries, including the United Kingdom, Canada, Denmark and Japan.